(Q34707006)

4 August 2017

1 reference

title

Bosentan: a dual endothelin receptor antagonist (English)

1 reference

4 August 2017

Lewis J Rubin

1

1 reference

4 August 2017

Sébastien Roux

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Expert Opinion on Investigational Drugs

4 August 2017

published in

1 reference

4 August 2017

volume

11

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

991-1002

1 reference

Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Role of endothelin in the increased vascular tone of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Primary pulmonary hypertension. A national prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Recognition and management of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

EndothelinB receptor-mediated contraction in human pulmonary resistance arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Endothelin antagonism with bosentan: a review of potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Characterization of the pulmonary arterial response to endothelin-1 and bosentan in neonatal pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Differential effects of the mixed ET(A)/ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Effects of the endothelin receptor antagonist Bosentan on ischaemia/reperfusion injury in rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

Endothelin-1 in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.7.991

10.1517/13543784.11.7.991

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference